|
|
Vaccine Detail
|
Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007039
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: CEACAM5
- Cea-Mouse
gene engineering:
- Preparation: The vaccine is a recombinant (r) vaccinia-based vector containing the transgenes encoding for the costimulatory molecules B7.1, ICAM-1, and LFA-3 (Duggan et al., 2016).
- Description: This is for Solid Tumors (NCT00217373). A vaccine consisting of recombinant vaccinia virus encoding the tumor-associated antigen carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1, and LFA-3; also called TRICOM). Vaccination with recombinant vaccinia-CEA(6D)-TRICOM vaccine stimulates the host immune system to mount a T-cell response against tumor cells expressing the CEA antigen. The use of TRICOM in the vaccine may elicit a greater antitumor cytotoxic T lymphocyte (CTL) immune response compared to the use of vaccinia-CEA alone (NCIT_C2619).
|
| Host Response |
|
|
| References |
Duggan et al., 2016: Duggan MC, Jochems C, Donahue RN, Richards J, Karpa V, Foust E, Paul B, Brooks T, Tridandapani S, Olencki T, Pan X, Lesinski GB, Schlom J, Carson Iii WE. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-?-2b in patients with CEA-expressing carcinomas. Cancer immunology, immunotherapy : CII. 2016; 65(11); 1353-1364. [PubMed: 27581603].
NCIT_C2619: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2619]
NCT00217373: [https://clinicaltrials.gov/show/NCT00217373/]
|
|
